High BP Seen at School Age for Extreme Preterm Infants

Share this content:
High BP Seen at School Age for Extreme Preterm Infants
High BP Seen at School Age for Extreme Preterm Infants

THURSDAY, Aug. 9, 2018 (HealthDay News) -- Both overweight and normal-weight children who were born as extreme preterm (EPT) infants are at risk for high blood pressure (BP) and hypertension, according to a study published in the August issue of Pediatrics.

Betty R. Vohr, M.D., from Brown University in Providence, R.I., and colleagues evaluated rates of high BP (≥90th percentile) and hypertension (BP ≥95th percentile) and associated risk factors among 379 EPT infants at 6 to 7 years of age.

The researchers found that 20.6 percent of study participants had systolic high BP, 10.8 percent had systolic hypertension, 21.4 percent had diastolic high BP, and 11.4 percent had diastolic hypertension. Higher rates of body mass index (BMI), triceps skinfolds >85th percentile, and waist circumference >90th percentile were seen in children with systolic high BP. Weight gain velocity from 18 months to school age (relative risk [RR], 1.36) and maternal gestational diabetes (MGD; RR, 2.04) predicted systolic and either systolic or diastolic high BP (RR, 1.27 and 1.67, respectively). Prevalence of systolic and diastolic high BP was 17 and 19 percent, respectively, among children with BMI <85th percentile. In normal-weight children, public insurance (RR, 2.46) and MGD (RR, 2.16) predicted systolic high BP, and MGD (RR, 2.08) predicted either systolic or diastolic high BP.

"Findings of high BP among EPT children at early school age are worrisome and indicate a need for close follow-up," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »